Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Infection ; 2024 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-38381306

RESUMEN

PURPOSE: This aimed to identify the factors associated with severe/critical coronavirus disease 2019 (COVID-19) infection in rheumatoid arthritis (RA) patients. METHODS: Two-hundred RA patients diagnosed according to the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria with proven COVID-19 infection were recruited and categorized according to the world health organization (WHO) COVID-19 severity grading into 2 groups: patients with mild/moderate COVID-19 (n = 164) and patients with severe/critical COVID-19 (n = 36). Comparison between both groups was done to identify the risk factors associated with severe/critical infection. Incidence of RA disease activity flare defined as increase in clinical disease activity index (CDAI) more than 10 points following infection was calculated. RESULTS: Multivariate analysis identified history of previous serious infection, age > 60 years, and diabetes as factors positively associated, whereas COVID-19 vaccination was negatively associated with severe/critical infection. Following COVID-19 infection, the number of patients with severe/critical COVID-19 who had high RA disease activity and the incidence of flares was significantly higher in comparison to patients with mild/moderate COVID-19 (P < 0.001 and 0.003; respectively). CONCLUSION: Age > 60 years, diabetes, and history of previous serious infections are risk factors for severe/critical COVID-19, while vaccination has a protective role in RA patients. Infection particularly when severe is associated with risk of disease flare.

2.
Rheumatol Int ; 43(4): 667-676, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36617362

RESUMEN

To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.


Asunto(s)
Artritis Reumatoide , Reumatología , Masculino , Femenino , Humanos , Egipto/epidemiología , Anticuerpos Antiproteína Citrulinada , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/epidemiología , Factor Reumatoide , Autoanticuerpos , Péptidos Cíclicos/uso terapéutico
3.
Rheumatol Int ; 32(7): 2075-81, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21487697

RESUMEN

Increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA) patients cannot be entirely explained by traditional risk factors, suggesting that systemic inflammation characterizing this disease may accelerate atherosclerosis. Technetium 99m-Methoxyisobutyl isonitrile (Tc-99m sestamibi) is a myocardial perfusion imaging agent that has been suggested for evaluation of peripheral vascular disease. We used Tc-99m sestamibi muscle scan to investigate the prevalence of preclinical atherosclerosis in RA patients by perfusion reserve (PR) measurement. This study included 25 RA patients and 25 controls; 13/25 RA (GII) were on glucocorticoids and 12/25 (GI) were not. Database included full history, clinical examination, relevant laboratory tests, and Tc-99m sestamibi muscle scan for lower limbs. The percentage increase in the total counts (Cts) in the exercising calf termed PR was calculated according to the formula: (PR %) = (Cts in exercising calf-Cts in resting calf) ÷ (Cts in resting calf) × 100%. A significant difference was found between the means of PR in RA and controls (30.7±22.6% vs. 48.3±27.2%, P = 0.015). The mean perfusion reserve of GII correlated significantly with the steroids cumulative dose (P = 0.01). A statistically significant negative correlation was elicited between PR and disease duration (P = 0.024), while the negative correlation between PR and Disease Activity Index (DAS28) was not statistically significant (P = 0.065). Tc-99m sestamibi lower-limb muscle scan could be a useful screening tool for detection of preclinical atherosclerosis in lower limbs of RA patients, so early prophylactic measures and therapy modifications could be considered.


Asunto(s)
Artritis Reumatoide/diagnóstico por imagen , Aterosclerosis/diagnóstico , Extremidad Inferior/diagnóstico por imagen , Músculo Esquelético/diagnóstico por imagen , Radiofármacos , Tecnecio Tc 99m Sestamibi , Adulto , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Diagnóstico Precoz , Femenino , Glucocorticoides/uso terapéutico , Humanos , Extremidad Inferior/irrigación sanguínea , Persona de Mediana Edad , Músculo Esquelético/irrigación sanguínea , Músculo Esquelético/efectos de los fármacos , Cintigrafía
4.
Reumatol Clin (Engl Ed) ; 15(5): 258-263, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-29276053

RESUMEN

OBJECTIVES: To assess the inter-observer agreement of standard joint count between experienced Rheumatology professor (Prof) and young Rheumatology fellow (candidate), and to compare disease global assessment between professor, young candidate and patients. METHODS: This study included one hundred rheumatoid arthritis patients. For all patients independent clinical evaluation was done by two rheumatologists (professor and candidate) for detection of tenderness in 28 joints and swelling in 26 joints. The study also involved global assessment of disease activity by the provider (Prof and candidate) (EGA) as well as by the patient (PGA). The EGA was determined without previous knowledge of the patient's laboratory test results. RESULTS: A highly significant accordance (correlation) between professor and candidate was found in both the number of tender joints (p<0.001) (r=0.946), and the number of swollen joints (p<0.001) (r=0.797). Regarding swollen joints, the highest agreement was in right knee (0.929), while poor agreement was found in the right 5th MCP (0.049). Regarding tender joints, the highest analogy was in the right elbow (0.899), in contrast to the left 3rd PIP (0.462) which showed the least congruence. Agreement study using kappa measurement for disease global assessment showed: moderate agreement (between professor and candidate) (0.405), fair agreement between (professor and patient) (0.213), fair agreement between (candidate and patient) (0.367). CONCLUSION: Inter-observer reliability was better for TJCs than SJCs. Regarding SJCs agreement was better in large joints such as the knees compared to the small joints such as the MCPs. Disease global assessment may show discrepancy between patients and physicians.


Asunto(s)
Artralgia/diagnóstico , Artritis Reumatoide/diagnóstico , Docentes Médicos , Internado y Residencia , Articulaciones/patología , Reumatología , Adulto , Anciano , Artritis Reumatoide/patología , Egipto , Femenino , Humanos , Articulación de la Rodilla/patología , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Medición de Resultados Informados por el Paciente , Examen Físico , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Adulto Joven
5.
Int J Rheum Dis ; 18(3): 268-75, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24620997

RESUMEN

Early diagnosis and early initiation of disease-modifying antirheumatic drug (DMARD) therapy slow the progression of joint damage and decrease the morbidity and mortality associated with rheumatoid arthritis (RA). According to the European League Against Rheumatism (EULAR) guidelines, treatment should be initiated with methotrexate and addition of biological DMARDs such as tumour necrosis factor (TNF) inhibitors should be considered for RA patients who respond insufficiently to methotrexate and/or other synthetic DMARDs and have poor prognostic factors. Africa and the Middle East is a large geographical region with varying treatment practices and standards of care in RA. Existing data show that patients with RA in the region are often diagnosed late, present with active disease and often do not receive DMARDs early in the course of the disease. In this review, we discuss the value of early diagnosis and remission-targeted treatment for limiting joint damage and improving disease outcomes in RA, and the challenges in adopting these strategies in Africa and the Middle East. In addition, we propose an action plan to improve the overall long-term outlook for RA patients in the region.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/tratamiento farmacológico , África/epidemiología , Artritis Reumatoide/epidemiología , Diagnóstico Precoz , Humanos , Medio Oriente/epidemiología , Guías de Práctica Clínica como Asunto , Valor Predictivo de las Pruebas , Mejoramiento de la Calidad , Indicadores de Calidad de la Atención de Salud , Inducción de Remisión , Factores de Tiempo , Resultado del Tratamiento
6.
Reumatol. clín. (Barc.) ; 15(5): 258-263, sept.-oct. 2019. tab
Artículo en Inglés | IBECS (España) | ID: ibc-189401

RESUMEN

OBJECTIVES: To assess the inter-observer agreement of standard joint count between experienced Rheumatology professor (Prof) and young Rheumatology fellow (candidate), and to compare disease global assessment between professor, young candidate and patients. METHODS: This study included one hundred rheumatoid arthritis patients. For all patients independent clinical evaluation was done by two rheumatologists (professor and candidate) for detection of tenderness in 28 joints and swelling in 26 joints. The study also involved global assessment of disease activity by the provider (Prof and candidate) (EGA) as well as by the patient (PGA). The EGA was determined without previous knowledge of the patient's laboratory test results. RESULTS: A highly significant accordance (correlation) between professor and candidate was found in both the number of tender joints (p < 0.001) (r=0.946), and the number of swollen joints (p < 0.001) (r=0.797). Regarding swollen joints, the highest agreement was in right knee (0.929), while poor agreement was found in the right 5th MCP (0.049). Regarding tender joints, the highest analogy was in the right elbow (0.899), in contrast to the left 3rd PIP (0.462) which showed the least congruence. Agreement study using kappa measurement for disease global assessment showed: moderate agreement (between professor and candidate) (0.405), fair agreement between (professor and patient) (0.213), fair agreement between (candidate and patient) (0.367). CONCLUSION: Inter-observer reliability was better for TJCs than SJCs. Regarding SJCs agreement was better in large joints such as the knees compared to the small joints such as the MCPs. Disease global assessment may show discrepancy between patients and physicians


OBJETIVOS: Evaluar el acuerdo interobservador del recuento de articulaciones estándar entre el profesor experimentado y el candidato joven, y comparar la evaluación global de la enfermedad entre el profesor, el candidato joven y los pacientes. MÉTODOS: Este estudio incluyó a 100 pacientes con artritis reumatoide. Para todos los pacientes, la evaluación clínica independiente fue realizada por 2 reumatólogos (profesor y candidato) para la detección de la sensibilidad en 28 articulaciones y la hinchazón en 26 articulaciones. También en este estudio evaluaciones globales de la actividad de la enfermedad por el proveedor (prof y candidato) Se realizó el paciente (PGA) para cada paciente. El EGA se determinó sin conocimiento previo de los resultados de la prueba de laboratorio del paciente. RESULTADOS: Se encontró una concordancia altamente significativa (correlación) entre el profesor y el candidato tanto en el número de articulaciones sensibles (p <0.001) (r = 0.946), y el número de articulaciones inflamadas (p <0.001) (r = 0.797). En cuanto a las articulaciones inflamadas, el mayor acuerdo fue en la rodilla derecha (0,929), mientras que el acuerdo pobre fue encontrado en el 5to MCP derecho (0.049). En cuanto a las articulaciones sensibles, la mayor analogía fue en el codo derecho (0,899), encontraste con el tercer PIP izquierdo (0.462) que mostró la menor congruencia. El estudio del acuerdo utilizando la medición kappa para la evaluación global de la enfermedad mostró: Acuerdo moderado (entre profesor y candidato) (0,405), Acuerdo justo entre (profesor y paciente) (0.213), Acuerdo justo entre (candidato y paciente) (0,367). CONCLUSIÓN: La con fiabilidad entre observadores fue mejor para TJCs que SJCs. Con respecto a los SJC, el acuerdo fue mejor en las articulaciones grandes, como las rodillas en comparación con las articulaciones pequeñas, como los MCP. La evaluación global de la enfermedad puede mostrar discrepancias entre los pacientes y los médicos


Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Artralgia/diagnóstico , Artritis Reumatoide/diagnóstico , Facultades de Medicina , Internado y Residencia , Articulaciones/patología , Reumatología , Artritis Reumatoide/patología , Egipto , Articulación de la Rodilla/patología , Variaciones Dependientes del Observador , Examen Físico , Índice de Severidad de la Enfermedad
7.
Clin Rheumatol ; 32(2): 151-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23274756

RESUMEN

Although the prevalence of RA in the Middle East and Africa is comparable with that in other parts of the world, evidence indicates that its management in this region is suboptimal for a variety of reasons, including misconceptions and misunderstandings about the disease's prevalence and severity in the region, compounded by the lack of local epidemiological and health-economic data around the disease; the perception that RA is a low priority compared with other more prevalent conditions; delayed diagnosis, referral and treatment; and a lack of a region-specific, evidence-based management approach. In the absence of such an approach, the EULAR treatment recommendations may provide a useful starting point for the creation of guidelines to suit local circumstances. However, although agreement with the EULAR recommendations is high, many barriers prevent their implementation in clinical practise, including lack of timely referral to rheumatologists; suboptimal use of synthetic DMARDs; poor access to biologics; lack of awareness of the burden of RA among healthcare professionals, patients and payers; and lack of appropriate staffing levels.To optimise the management of RA in the Middle East and Africa, will require a multi-pronged approach from a diverse group of stakeholders-including local, national and regional societies, such as the African League of Associations in Rheumatology and International League of Associations for Rheumatology, and service providers-to collect data on the epidemiology and burden of the disease; to increase awareness of RA and its burden among healthcare professionals, payers and patients through various educational programmes; to encourage early referral and optimise use of DMARDs by promoting the EULAR treatment recommendations; to encourage the development of locally applicable guidelines based on the EULAR treatment recommendations; and to facilitate access to drugs and the healthcare professionals who can prescribe and monitor them.


Asunto(s)
Artritis Reumatoide/epidemiología , Artritis Reumatoide/terapia , Países en Desarrollo , Guías de Práctica Clínica como Asunto , Reumatología/normas , África , Artritis Reumatoide/diagnóstico , Humanos , Medio Oriente , Prevalencia
8.
Clin Rheumatol ; 31(3): 407-16, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22228237

RESUMEN

Biologics, including tumor necrosis factor (TNF) inhibitors, are increasingly used for the treatment of inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis. The efficacy of these drugs has been demonstrated in randomized controlled trials (RCTs). However, these studies are conducted in controlled environments, and the results may not necessarily reflect clinical outcomes in daily clinical practice. In Europe and other western countries, numerous biologics registries that enroll and monitor patients receiving biologics have been established. These registries follow patients irrespective of whether they continue with the initial biologic drug. Thus, real-life efficacy data from these registries can be used to assess the long-term safety of biologics through longitudinal studies. In Africa and Middle East (AFME), such registries currently exist only in Morocco and South Africa. In light of the increasing availability of biologics and scarcity of long-term safety data of these agents in the AFME population, there is a need to establish biologics registries in other countries across the region. This review discusses the value of biologics registries versus RCTs as well as safety and efficacy data from observational studies presented as lessons from well-established biologics registries. In addition, the rationale for establishing such registries in the AFME region is also presented.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Sistema de Registros , Enfermedades Reumáticas/tratamiento farmacológico , África , Humanos , Medio Oriente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA